Sorrento Therapeutics Reports Promising Data From an Uncontrolled Clinical Trial

Sorrento Therapeutics' (NASDAQ: SRNE) COVI-MSC seems likes promising therapy for COVID-19 after the first four patients treated with the stem cell therapy were released from the hospital. But in this video from Motley Fool Live, recorded on Feb. 1, Fool.com contributors Brian Orelli and Keith Speights discuss why investors shouldn't read too much into the initial uncontrolled results.

Continue reading

Source Fool.com